Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

11 clinical studies listed.

Filters:

Respiratory

Tundra lists 11 Respiratory clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

NOT YET RECRUITING

NCT07950761

Impact of Clesrovimab on Respiratory Pathogen Shedding in Infants: The RSV-SHIELD Trial

RSV-SHIELD: Study Summary RSV-SHIELD is an investigator-initiated, prospective, single-centre, single-blind, Phase IV, randomised, placebo-controlled clinical trial designed to investigate the effects of passive immunoprophylaxis with clesrovimab, a long-acting monoclonal antibody against respiratory syncytial virus (RSV), on nasopharyngeal pathogen carriage, respiratory microbial ecology, and local immune responses in infants. The study aims to evaluate whether RSV prevention with clesrovimab influences not only RSV detection, viral load, and shedding dynamics but also the acquisition, persistence, and clearance of other respiratory viruses and bacterial pathogens. In addition, it will investigate changes in the nasopharyngeal microbiome and local inflammatory responses following immunoprophylaxis. These findings may provide novel insights into the interactions between RSV, other respiratory pathogens, and the developing respiratory microbiome, as well as the potential indirect effects of RSV immunoprophylaxis beyond the prevention of RSV-associated disease. Approximately 162 healthy infants aged 0-12 months, born at a gestational age of at least 32 weeks, will be recruited at the Department of Paediatrics, University General Hospital of Heraklion, Crete, Greece. Eligible infants will fall within the approved age indication for clesrovimab but will not qualify for RSV monoclonal antibody prophylaxis under the current Greek National Immunisation Programme. Participants will be randomised in a 1:1 ratio to receive either a single intramuscular dose of clesrovimab (105 mg) or matching placebo (0.9% normal saline). Participants will be followed for approximately eight months, with scheduled visits at baseline and months 1, 2, 3, and 5, an interim telephone assessment at month 4, and a final telephone follow-up at month 8. Additional visits will be conducted during episodes of acute respiratory tract infection. Nasopharyngeal specimens will be collected longitudinally to assess RSV detection and viral load, other respiratory viruses, and bacterial colonisation, including Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, Staphylococcus aureus, and Streptococcus pyogenes. Nasopharyngeal microbiome composition and diversity will be investigated using 16S rRNA sequencing. Nasal lining fluid will also be collected to measure clesrovimab concentrations and local inflammatory biomarkers. The primary objectives encompass RSV detection and shedding dynamics, non-RSV respiratory pathogen carriage and acquisition, and changes in the nasopharyngeal microbiome and inflammatory environment. Secondary outcomes include the incidence and clinical characteristics of respiratory tract infections, including bronchiolitis, pneumonia, acute otitis media, and wheezing episodes, as well as healthcare utilisation and hospitalisations. Adverse events and serious adverse events will be monitored throughout the study. By combining a randomised controlled design with longitudinal molecular, microbiological, and immunological assessments, RSV-SHIELD seeks to generate evidence on the broader biological effects of RSV monoclonal antibody prophylaxis. The findings may contribute to a better understanding of respiratory pathogen interactions in early life and inform future RSV prevention strategies. Approximately 3,400 characters, including spaces - within your 5,000-character limit.

Gender: All

Ages: 0 Days - 12 Months

Updated: 2026-11-20

RSV Infections
Pneumococcal Carriage
Respiratory
RECRUITING

NCT07823036

Assessing Pulmonary Changes in HSCT

This will be an un-blinded, open-label study of children and adults, including those who are being evaluated for or who have undergone HSCT, those with existing respiratory conditions and/or diagnosed gas-exchange impairment, and healthy control volunteers. The participants will be male or female between 3-17 years old (children) and adults age 18 and older. The study objective is to: * To optimize the acquisition of images reflecting the "dissolved-phase" Xe distribution in the pulmonary tissues and blood (Xe gas-exchange MRI). * To develop and test Xe MRI acquisition strategies that separately image alveolar airspace distribution (ventilation), as well as Xe dissolved in pulmonary tissues versus red blood cells (RBCs). * To acquire images of Xe ventilation and dissolved-phase Xe regional distribution in the enrolled participants. * To understand the same-day variability of Xe MRI techniques. * To determine the relationship between Xe MRI and clinical measures such as pulmonary-function-test (PFT) parameters or other biological biomarkers. * To develop and optimize strategies for Xe MRI in young children including those who are unable to follow the inhalation and breath-hold instructions typical of the Xe MRI procedure.

Gender: All

Ages: 3 Years - Any

Updated: 2026-11-12

1 state

HSCT
Respiratory
Gas Exchange Impairment
ACTIVE NOT RECRUITING

NCT06716463

PREdicting Failure of Non-inVasIve Ventilatory Support Using Non-invaSIve mONitoring in Non-intubated Patients With Acute Hypoxemic Respiratory Failure or Post-extubation Failure. The PREVISION Study

The goal of this observational study is to assess the potential non-invasive tools (e.g. regional ventilation, respiratory muscle response, lung mechanic's parameters) to identify the risk of failure when using high flow nasal cannula (HFNC) or non-invasive ventilation (NIV). The main question, it aims to answer is: Does abnormal regional ventilation could predict HFNC or NIV failure?

Gender: All

Ages: 18 Years - Any

Updated: 2026-11-10

1 state

Ventilatory Failure
Hypoxemic Respiratory Failure
Weaning Failure
+1
RECRUITING

NCT07845708

Proton MRI of MSK Disorders

In this research study, the investigators want to learn about new ways to use MRI (Magnetic Resonance Imaging) to take clearer pictures of the lungs. The investigators will be using types of MRI called UTE (Ultra Short Echo Time) and bSSFP (balanced Steady-State Free Precession) as well as traditional MRI. The investigators also want to collect images and health information about lungs that are healthy or those in people with different kinds of lung, muscular, and bone diseases. This collection will help us in the future to better understand lung variations in health and disease.

Gender: All

Ages: 5 Years - Any

Updated: 2026-10-16

1 state

Muskuloskeletal Diseases
Healthy
Respiratory
RECRUITING

NCT07431021

Children's Health, Respiratory Inflammation and Short-term Air Pollution

The goal of this study is to see if physical activity in high air pollution is worse than rest in high air pollution.

Gender: All

Ages: 7 Years - 11 Years

Updated: 2026-06-15

Asthma Acute
Respiratory
RECRUITING

NCT07391280

Strategy for EArly Recognition of Cancer, COPD & Heart Failure in the Emergency Department

SEARCH-ED is a research study which is running in Emergency Department (ED) of the Queen Elizabeth University Hospital. The aim of the study is to find out if using a computer programme can help doctors diagnose heart and lung problems from chest x-rays. We want to compare how many people are diagnosed with heart or lung problems for the first time when doctors have access to the computer programme results, in comparison to when they don't.

Gender: All

Ages: 18 Years - Any

Updated: 2026-06-01

Cancer
Cardiovascular
Respiratory
WITHDRAWN

NCT07223294

Study to Evaluate the Therapeutic Equivalence and Safety of Fluticasone Furoate and Vilanterol Inhalation Powder 100 mcg/25 mcg and BREO ELLIPTA 100 mcg/25 mcg in Participants With Asthma

This is a randomized, multi-center, multiple-dose, double-blind, placebo-controlled, Parallel group design, clinical endpoint bioequivalence study in adult participants with asthma. The study design includes up to a 2-week Screening period, at least a 2-week Run-in period, a 4-week Treatment period, and a safety follow up call one week later. Visit 1: Screening Visit 2: Run-in period: All eligible participants will enter a 2-week Run-in period in which training will be provided to the participants on the use of inhalers and participant diary. Visit 3: Day 1: Randomization to one of the 3 treatment groups to receive one inhalation of the study medication quaque die (QD), in the morning, for 28 ± 2 days. Visit 4: Day 28: EOT Participants will be contacted one week after their last site visit for Safety follow-up via phone call (end of study). Participants will be instructed to refrain from taking their current inhaled asthma medications from the start of the Run-in period until the end of treatment (EOT) visit. They will be provided with a salbutamol/albuterol inhaler (rescue medication) for use on an as-needed basis during the entire study duration until the EOT visit.

Gender: All

Ages: 18 Years - 75 Years

Updated: 2026-05-12

Respiratory
NOT YET RECRUITING

NCT07378852

Integrated Study on Gut Microbiota, Immune Indicators, and Trace Elements in Children With Respiratory Tract Infections

This observational study aims to investigate the characteristics of gut microbiota and their associations with immune and nutritional indicators in children with different respiratory health statuses. A total of 120 children will be enrolled and categorized into four groups: children with Mycoplasma pneumoniae pneumonia (MPP), children with acute respiratory tract infections without Mycoplasma pneumoniae (NMP), children with recurrent respiratory tract infections (RRTIs), and healthy controls. By comparing gut microbiota composition and diversity, as well as immune- and nutrition-related indicators across groups, this study seeks to clarify the potential role of intestinal dysbiosis and host immune-nutritional interactions in the pathogenesis and clinical manifestations of pediatric respiratory tract infections.

Gender: All

Ages: 3 Years - 14 Years

Updated: 2026-02-04

2 states

Respiratory
RECRUITING

NCT07293299

The PneumoRator Study

Healthcare workers measure heart rate, blood pressure, temperature, oxygen levels and breathing rate to monitor how unwell a patient is. All these apart from breathing rate are now normally measured by machines. But there still isn't a machine that does this well enough for breathing rate to be used in most places. The machines that do exist are either uncomfortable or don't work well on patients who are moving. Instead, a healthcare worker will count the number of breaths a patient takes. This needs staff time and isn't very accurate. It is known that changes in breathing rate can happen any time. But healthcare systems normally only measure it every few hours because it takes time. Breathing rate could be monitored all the time, we might pick up people getting sick earlier and be able to treat them more quickly, which could save lives. A team at the University of Southampton has made a small device, called a PneumoRator, that gets stuck to onto a person's chest. Once stuck there it can measure their breathing rate and store or send that information wirelessly. The device has been tested on healthy volunteers but has never been tested on patients in hospital. In this study the team will put the device on patients having major operations. The investigators will record information already collected about patients during normal care. This includes their breathing rate using the best measurement we have, where a patient's breathing is measured by a gas they breathe out. The gas is carbon dioxide, and the measurement is called capnography. This way of measuring is only used in operating theatres and intensive care units but is a good way to check if the PneumoRator is accurate. The investigators want to attach the PneumoRator to patient's chests before they go to sleep for their operation and leave it there for the first few days after their operation. This will let them see how the PneumoRator compares to capnography and manual breath counting. It will also let them see how the device works at different times in the patient's journey. The investigators will look at the time when patients are asleep, when breathing is controlled by a machine. Then when patients wake up investigators can measure with both capnography and the PneumoRator. Finally, when patients go to the high dependency ward, investigators will compare it against manual counting. The study team will also ask patients how they found wearing the device and any problems they found. With this information the investigators hope to show the PenumoRator is accurate at measuring breathing rate and comfortable for patients. This will help them get the device approved for use in hospitals and other places where breathing rate needs to be measured accurately.

Gender: All

Ages: 18 Years - Any

Updated: 2025-12-19

Respiratory
Monitored Anaesthesia Care
Perioperative
RECRUITING

NCT05505110

MOdification Of THe Early-Life Respiratory Microbiome Through Vaginal SEEDing

This is a single-center, parallel-arm, blind, sham-controlled, feasibility randomized controlled trial (RCT) to be conducted in healthy cesarean-born children. Eligible children will be randomized 1:1 to have their nose swabbed with either maternal vaginal secretions or a sterile swab (intervention vs. control group, respectively). The main hypothesis is that conducting an RCT assessing the utility of vaginal seeding in modifying the early-life upper respiratory tract (URT) microbiome of children born by cesarean section (C-section) is feasible and that the intervention is safe.

Gender: FEMALE

Ages: 18 Years - 40 Years

Updated: 2025-11-10

1 state

C-section
Vaginal Seeding
Respiratory
+1
ACTIVE NOT RECRUITING

NCT06670560

Onco-Respirology Epidemiology Based on Real-world Big Data in Respiratory Medicine

The purpose of this observational study is to understand the changes in the types of respiratory patients hospitalized in China in recent years through a multicenter retrospective clinical study, and at the same time to understand the reasons for hospitalization and the distribution of different tumor types in oncology patients, so as to provide data support and theoretical basis for the future development of China's respiratory department. The main questions it aims to answer are 1. the trend of change of respiratory diseases in China in the past 10 years. 2. the trend of change in the causes of hospitalization of respiratory tumor patients in China in the past 10 years. 3. the trend of the proportion of each tumor in the respiratory department in China over the past 10 years.

Gender: All

Updated: 2024-11-07

1 state

Respiratory
Epidemiology
Neoplasms